

Arch Therapeutics, Inc.
Form SC 13G/A
February 09, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 3)*

Arch Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

003939W 109

(CUSIP Number)

Michael Parker

1928 East Highland Avenue, Suite F104-558

Phoenix, Arizona 85016

(480) 717-0911

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

December 31, 2016

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 003939W 109
 13G
 Page 2 of 6
 Pages

NAMES OF REPORTING
 PERSONS

I.R.S. IDENTIFICATION

1. NOS. OF ABOVE
 PERSONS (ENTITIES
 ONLY)

Michael Parker

CHECK THE
 APPROPRIATE BOX IF
 A MEMBER OF A

2. GROUP
 (see instructions)
 (a)
 (b)
 3. SEC USE ONLY

4. CITIZENSHIP OR PLACE
 OF ORGANIZATION

United States

SOLE VOTING
 POWER

5. 9,911,667 shares
 of Common Stock
 Series D Warrants
 to purchase up to
 4,500,000 shares
 of Common Stock,
 which will expire
 on June 30, 2020
 (see item 4)*.
 Series E Warrants
 to purchase up to
 1,583,334 shares
 of Common Stock,
 which will expire
 on May 26, 2021
 (see item 4)*.

SHARED
 VOTING POWER

6. NUMBER
 OF
 SHARES
 BENEFICIALLY
 OWNED
 BY
 EACH
 REPORTING

N/A

SOLE
DISPOSITIVE
POWER

- 9,911,667 shares
of Common Stock
(1)
Series D Warrants
to purchase up to
4,500,000 shares
7. of Common Stock,
which will expire
on June 30, 2020
(see item 4)* (2)
Series E Warrants
to purchase up to
1,583,334 shares
of Common Stock,
which will expire
on May 26, 2021
(see item 4)* (3)

8. SHARED
DISPOSITIVE
POWER

N/A

AGGREGATE AMOUNT
BENEFICIALLY OWNED BY
EACH REPORTING PERSON

- 9,911,667 shares of Common Stock
(1)
9. Series D Warrants to purchase up to
4,500,000 shares of Common Stock,
which will expire on June 30, 2020
(see item 4)* (2)
Series E Warrants to purchase up to
1,583,334 shares of Common Stock,
which will expire on May 26, 2021
(see item 4)* (3)
10. CHECK IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES
(see instructions)
11. PERCENT OF CLASS
REPRESENTED BY AMOUNT IN
ROW (9)
7.19% (see Item 4)*
(1) 2,164,837 shares of Common
Stock owned individually by Michael

Parker; 2,746,830 shares of Common Stock owned individually by Ana B Parker, spouse of Michael Parker; and 5,000,000 shares of Common Stock owned through Tungsten III LLC, of which Michael Parker is the sole manager.

(2) 4,500,000 Series D Warrants to purchase up to 4,500,000 shares of Common Stock, which expire on June 30, 2020, owned through Tungsten III LLC, of which Michael Parker is the sole manager.

(3) 1,583,334 Series E Warrants to purchase up to 1,583,334 shares of Common Stock, which expire on May 26, 2021, owned through Tungsten III LLC, of which Michael Parker is the sole manager.

TYPE OF REPORTING PERSON
(see instructions)

12. Michael Parker – IN

Ana B Parker – IN

Tungsten III, LLC - OO

* As more fully described in Item 4, certain of these reported securities are subject to a 4.9% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon fully exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (5), (7) and (9).

CUSIP No. 003939W 109 13G Page 3 of 6 Pages

Item 1.

- (a) Name of Issuer
Arch Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices
235 Walnut Street, Suite 6, Framingham, MA 01702

Item 2.

- (a) Name of Person Filing
Michael Parker
- (b) Address of the Principal Office or, if none, residence
1928 East Highland Avenue, Suite F104-558, Phoenix, Arizona 85016
- (c) Citizenship
United States
- (d) Title of Class of Securities
Common Stock, par value \$0.001 per share
- (e) CUSIP Number
003939W 109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

CUSIP No. 003939W 109 13G Page 4 of 6 Pages

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Amount beneficially owned: 9,911,667 shares of Common Stock (1)

- (a) Series D Warrants to purchase up to 4,500,000 shares of Common Stock, which expire on June 30, 2020 (2)
- Series E. Warrants to purchase up to 1,583,334 shares of Common Stock, which will expire on May 26, 2021 (3)

(b) Percent of class: 7.19%

(c) Number of shares as to which the person has:

Sole power to vote or to direct the vote 9,911,667 shares of Common Stock (1)

Series D Warrants to purchase up to 4,500,000 shares of Common Stock, which will expire on June 30, 2020

(i) (2)

Series E. Warrants to purchase up to 1,583,334 shares of Common Stock, which will expire on May 26, 2021

(3)

(ii) Shared power to vote or to direct the vote 0.

Sole power to dispose or to direct the disposition of 9,911,667 shares of Common Stock (1)

Series D Warrants to purchase up to 4,500,000 shares of Common Stock, which will expire on June 30, 2020

(iii)(2)

Series E. Warrants to purchase up to 1,583,334 shares of Common Stock, which will expire on May 26, 2021

(3)

(iv) Shared power to dispose or to direct the disposition of 0.

On the date of event which requires the filing of this Schedule 13G, Mr. Parker may have been deemed to be the beneficial owner of more than 7.19% of the Common Stock. The Company's 10-K filed on December 5, 2016, indicated that the total number of outstanding shares of Common Stock as of December 2, 2016, was 137,882,075. The percentage set forth on Row 11 of the cover page is based on the Company's outstanding Common Stock as assumes no exercise of the reported warrants due to the blocker (as defined below).

Pursuant to the terms of the reported warrants (the Reported Warrants), the Reporting Person cannot exercise any of the Reported Warrants until such time as the Reporting Person would not beneficially own, after such exercise, more than 4.9% of the outstanding shares of Common Stock (the Blocker) because such Reported Warrants contain ownership limitations pursuant to which the holder is prohibited from exercising such warrants to the extent (but only to the extent) that the exercise thereof would result in the holder or any of its affiliates beneficially owning more than 4.9% of the Common Stock after giving effect to such exercise; provided, however, that the holder may waive such ownership limitation, in which case such waiver will become effective sixty-one (61) days after the holder's delivery of such waiver notice. As of the date of this Schedule 13G, Mr. Parker has not waived such limitation.

2,164,837 shares of Common Stock owned individually by Michael Parker, 2,746,830 shares of Common Stock (1) owned individually by Mr. Parker's spouse, Ana B Parker, and 5,000,000 shares of Common Stock owned through Tungsten III LLC, of which Michael Parker is the sole manager.

4,500,000 Series D Warrants to purchase up to 4,500,000 shares of Common Stock, which expire on June 30, 2020, owned through Tungsten III LLC, of which Michael Parker is the sole manager and 1,583,334 Series E (2) Warrants to purchase 1,583,334 shares of Common Stock, which expire on May 26, 2021, owned through Tungsten III LLC, of which Michael Parker is the sole manager.

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

CUSIP No. 003939W 109 13G Page 5 of 6 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certification.

- (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

- (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 003939W 109 13G Page 6 of 6 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 6, 2017

Date

/Michael Parker/

Signature

Michael Parker

Name/Title